… In November, the first patient was dosed in the Phase 1/2 open-label trial (PQ-110-001) to assess the safety, … six adults (≥ 18 years) who have LCA 10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. During … expertise in genetic retinal disease in the U.S. and Europe. The objectives of the trial include safety, …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … period. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… that it further strengthened its leading intellectual property estate for ADAR-mediated RNA editing by successfully defending against an opposition filed in Japan by a strawman against ProQR’s … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
… biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of … its Therapeutic Development Network, a network of CF key opinion leaders, as well as to an extensive clinical trial …